Trial reportThe Lancet. Oncology2022
Atezolizumab, vemurafenib, and cobimetinib in patients with melanoma with CNS metastases (TRICOTEL): a multicentre, open-label, single-arm, phase 2 study.
Trial report in The Lancet. Oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It has been retracted, and should not be counted. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 42 citations in OpenAlex.
- The role of triple therapy and therapy sequence in treatment of BRAF-mutant metastatic melanoma. Response to overall survival with first-line atezolizumab in combination with vemurafenib and cobimetinib in BRAFV600 mutation-positive advanced melanoma (IMspire150): second interim analysis of a multicentre, randomised, phase 3 study.Journal of translational medicine · 2023Trial
- Clinical Features Associated with Outcomes and Biomarker Analysis of Dabrafenib plus Trametinib Treatment in Patients with BRAF-Mutant Melanoma Brain Metastases.Clinical cancer research : an official journal of the American Association for Cancer Research · 2023Trial
- Melanoma: Pathogenesis and Targeted Therapy.MedComm · 2026Review
- Biomarkers of immunotherapy response in neuro-oncology.Neuro-oncology advances · 2025Review
- Multidisciplinary management strategies for recurrent brain metastasis after prior radiotherapy: An overview.Neuro-oncology · 2025Review
- Immunotherapy combination approaches: mechanisms, biomarkers and clinical observations.Nature reviews. Immunology · 2024Review
- Primary Cutaneous Melanoma-Management in 2024.Journal of clinical medicine · 2024Article
- Molecular Targeting of the BRAF Proto-Oncogene/Mitogen-Activated Protein Kinase (MAPK) Pathway across Cancers.International journal of molecular sciences · 2024Review
- Leptomeningeal disease in melanoma: An update on the developments in pathophysiology and clinical care.Pigment cell & melanoma research · 2024Review
- Synergistic Immunoregulation: harnessing CircRNAs and PiRNAs to Amplify PD-1/PD-L1 Inhibition Therapy.International journal of nanomedicine · 2024Review
- Prediction of survival and immunotherapy response by the combined classifier of G protein-coupled receptors and tumor microenvironment in melanoma.European journal of medical research · 2023Article
- Advances in targeted therapy and immunotherapy for melanoma (Review).Experimental and therapeutic medicine · 2023Review
- Optical blood-brain-tumor barrier modulation expands therapeutic options for glioblastoma treatment.Nature communications · 2023Article
- Current Treatment of Melanoma Brain Metastases.Cancers · 2023Review
- Heterogeneity of the tumor immune microenvironment and clinical interventions.Frontiers of medicine · 2023Review
- Advances in the molecular mechanism and targeted therapy of radioactive-iodine refractory differentiated thyroid cancer.Medical oncology (Northwood, London, England) · 2023Review
- Macrophage's role in solid tumors: two edges of a sword.Cancer cell international · 2023Article
- Combination of immune-checkpoint inhibitors and targeted therapies for melanoma therapy: The more, the better?Cancer metastasis reviews · 2023Review
- Sequencing Targeted and Immune Therapy in BRAF-Mutant Melanoma: Lessons Learned.Current oncology reports · 2023Review
- Triple combinations of immunotherapy and targeted therapy in patients with melanoma with brain metastases.Annals of translational medicine · 2023Article
Corrections and comments
- Retraction · 2023-07-14Concerns/Issues about Data · Error in Results and/or Conclusions · Retract and Replace · Upgrade/Update of Prior Notice(s) · · see https://www.sciencedirect.com/science/article/pii/S1470204523003340; see also: https://www.sciencedirect.com/science/article/pii/S1470204523002929;
- Expression of concern · 2023-03-14Concerns/Issues about Data · Concerns/Issues about Results and/or Conclusions · Updated to Retraction ·
- Commented on by
- Commented on by
- Commented on by
- Commented on by
- Expression of concern
- RetractedandRepublishedIn
- Retracted
Authors and funding
15 authors at 11 institutions in 7 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundTargeted therapy and immunotherapy have shown intracranial activity in melanoma with CNS metastases, but there remains an unmet need, particularly for patients with symptomatic CNS metastases. We aimed to evaluate atezolizumab in combination with cobimetinib or vemurafenib plus cobimetinib in patients with melanoma with CNS metastases.
methodsTRICOTEL was a multicentre, open-label, single-arm, phase 2 study done in two cohorts: a BRAF
findingsBetween Dec 13, 2018, and Dec 7, 2020, 65 patients were enrolled in the BRAF
interpretationAdding atezolizumab to vemurafenib plus cobimetinib provided promising intracranial activity in patients with BRAF
fundingF Hoffmann-La Roche.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.